This study showed that Echi treatment had a beneficial effect on the level of ALT, AST, caspase-1, IL-1β, TNF-α, and lipid steatosis and fibrosis in the liver in MCD-induced NASH, which is similar to NLRP3 inhibitors, MCC950. Here, NLRP3 is linked to metabolic dysfunction-associated steatohepatitis.